Innovation Summit 2019: Marketplace

C4X Discovery (C4XD) aims to create the world’s most productive drug discovery engine by using cutting-edge technologies and expertise to efficiently deliver best-in-class small-molecule medicines to clinical partners for the benefit of patients. The Company’s business model focuses on replenishing big pharma discovery pipelines by driving returns through revenue generating pre-clinical licensing deals. In 2018, C4XD successfully out-licensed a pre-clinical programme in addictive disorders to Indivior in a deal worth up to $294m.

C4XD has a state-of-the-art suite of proprietary technologies across the drug discovery process and accesses further innovative capabilities and expertise through its growing network of partners. The Company is actively advancing its diverse pre-clinical discovery portfolio which is focused on oncology (including immuno-oncology), inflammation and neurodegeneration, and is seeking to work with innovative partners, from both academia and industry, that have novel therapeutic ideas that could benefit from C4XD’s discovery expertise and capabilities. Opportunities to maximise value from across the portfolio are proactively driven by C4XD’s commercial division. The Company is led by a highly experienced management team and Board who have delivered significant value creation within the healthcare sector.

     Find out more

PanaceaStars is a health and life sciences technology translation platform. We collaborate with the most exciting sci-entrepreneurs to help transform bold visions into thriving companies that improve people’s lives.

In partnership with CRUK comes OncoStars, for scientists, academics and entrepreneurs, working in the field of oncology. OncoStars is designed to inspire you to think about your research from a translational perspective, to spark your entrepreneurial appetite, and to help you build a start-up around your disruptive ideas. Join us, and get your groundbreaking science out of the lab, to diagnose, treat and prevent cancer.

     Find out more

Alembia Intellectual Property are a firm of UK Chartered and European Patent Attorneys specialising in pharmaceuticals, life sciences and chemistry. Based at the Alderley Park Accelerator, we provide strategic, outcome-focussed IP advice to our clients, who range from startups to SMEs to large multinationals. Our attorneys employ more than three decades of patent lifecycle experience to draft, prosecute and litigate patents, and we offer first class agreement, licensing and business development support, aiming to deliver truly value-adding IP portfolios.

     Find out more

Catapult Ventures is an independent venture capital fund manager that has been investing in UK businesses since 2002. Catapult's owners have operated discrete funds on behalf of public and private sector investors totalling c. £130m, including the GM&C Life Sciences Fund.

Since 2015 Catapult has recorded 11 profitable exits averaging 3.9x money multiple, including Accutronics (9.1x), Lumora (4.7x), Oxford Cryosystems (5.2x), Systems Integration (4.9x), Monica Healthcare (3.6x), BWB Consulting (3.2x*), Hangar7 (3x), Haemostatix (3x*) and Stagecoach (2x). [* expected]

     Find out more

Humanity faces a host of systematic challenges. Solving these challenges demands a radical new framework. The linear commercialisation models of academia and industry don't always capture the full potential of applied science. Deep Science Ventures was founded to create a better method for launching science companies, one that takes a systems level view of the opportunity from day one. Rather than spin-out companies on the back of IP, we take a step back and distill it down to the fundamental challenges within the system. Then, our global network of founder-type scientists build “holy grail” ventures that have the potential to redesign entire sectors.

     Find out more

Cancer Research UK has an impressive record of developing novel treatments for cancer. The Cancer Research UK Centre for Drug Development has been pioneering the development of new cancer treatments for 25 years, taking over 140 potential new anti-cancer agents into clinical trials in patients. It currently has a portfolio of around 20 new anti-cancer agents in preclinical development, Phase I or early Phase II clinical trials. Six of these new agents have made it to market including temozolomide for brain cancer, abiraterone for prostate cancer and rucaparib for ovarian cancer. Two other drugs are in late development Phase III trials. 

     Find out more

The Cancer Research UK-AstraZeneca Antibody Alliance Laboratory (CAZAAL) is a standalone lab formed through an innovative partnership bringing together Cancer Research UK’s cancer biology expertise with the world-class antibody engineering technology of AZ to support antibody discovery. CAZAAL uses AZ’s antibody phage display libraries and additional antibody capabilities to identify fit for purpose therapeutic, biomarker, and tool antibodies. We collaborate closely with academic scientists, to help realise the full potential of their novel biological insights and targets and to maximise the impact of breakthroughs made in the lab for cancer patients.

     Find out more